Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Within the broader context of the pharmaceutical i
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
For the first time in its chronicle, the pharmaceu
Since it’s an ingredient in so many foods, you h
Dear Readers,Welcome to the latest issue of Microb
One of the enduring problems that this United States Pharmacopeia (USP) is the need to establish guidelines for testing standards that represent common use. Dry powder inhalers that are passive (DPIs) depend solely on the inhalation effort produced by the patient in order to generate an aerosol that can be breathed. In the past, DPIs have been used to administer medication to aid in the immediate treatment or alleviation of chronic obstructive pulmonary disease (COPD) as well as asthma. Patients suffering from one or the other of these conditions, typically, suffer from diminished respiratory function, and may be less capable to breathe vigorously through an aerodynamically resistive DPI.
In this webinar you will learn:
Understand the Pharmacopoeial requirements and why these are important Find out all about the basics of OINDPs testing Learn all about DDU and APSD testing Understand the equipment that is key for your testing
Date: February 4th 2022
Time: 03:00 PM IST onwards
Speaker: Anna Sipitanou, Head of Business Development at Copley Scientific
Click here for registrations: https://meet.zoho.in/eEgFqW1LdH
To know more visit: https://www.copleyscientific.com/multiproducts/tbf-100i/
For more information: [email protected]
